Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis by Grégoire Desimpel, François Zammit, Sarah Lejeune, Guillaume Grisay, Emmanuel Seront

Subjects: Get full text

Dramatic Response to Enfortumab Vedotin in Soft-tissue Metastases from Urothelial Carcinoma: A Case Report by Ming-Hsuan Wu, Chung-Chieh Wang, Fu-Jen Hsueh

Subjects: “…enfortumab vedotin…”
Get full text

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma by Maura C. Gillis, BA, Vanessa R. Weir, BA, Cecilia Lezcano, MD, Gopa Iyer, MD, Allison Gordon, MD

Subjects: Get full text

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma by Takafumi Fukushima, Kazuyuki Numakura, Masanao Shinohara, Yohei Kawashima, Yuya Sekine, Kanami Mori, Mizuki Kobayashi, Himawari Asanuma, Takaki Ichiyama, Hisashi Sakurai, Kai Ozaki, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Satoshi Sato, Tomonori Habuchi, Chikara Ohyama, Shingo Hatakeyama

Subjects: Get full text

Anti-Cancer Drug-Induced Lyell’s Syndrome: A Series of Two Patients by Julie Coussirou, Magali Ravoire, Alma Stancu, Léa Vazquez

Subjects: Get full text

Enfortumab Vedotin–Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding by Aika Matsuyama, Takashi Kato, Rion Kawase, Mikinori Kobayashi, Ayako Momota, Yukiko Tsunoda, Asaomi Yamaguchi, Hiroki Hirabayashi, Shoji Suzuki, Masashi Kato

Subjects: “…enfortumab vedotin…”
Get full text

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis by Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Wataru Fukuokaya, Kosuke Iwatani, Renate Pichler, Jeremy Yuen-Chun Teoh, Marco Moschini, Wojciech Krajewski, Jun Miki, Shahrokh F. Shariat, Takahiro Kimura, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)

Subjects: Get full text

Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances by Albert Jang, Jason R. Brown

Subjects: Get full text

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherap... by Weiming Liang, Weiming Liang, Zhijing Wang, Zhilong Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Duo Zhang, Chenchen Li

Subjects: Get full text

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and R... by Catherine C. Fahey, Sean Clark-Garvey, Sima Porten, Ashish M. Kamat, Thomas W. Flaig, John A. Taylor, William Y. Kim, Matthew I. Milowsky

Subjects: Get full text

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure by Bożena Sikora-Kupis, Piotr Domański, Weronika Fortuniak, Barbara Kruczyk, Szymon Staneta, Mateusz Piętak, Anna Mydlak, Tomasz Demkow, Paulina Dumnicka, Jakub Kucharz

Subjects: Get full text

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomize... by Weiming Liang, Shibo Huang, Yanping Huang, Miaoyan Huang, Chunyan Li, Yiwen Liang, Li Pang

Subjects: Get full text

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience by Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park, Maria T. Bourlon, Enrique Grande, Francesco Massari, Johannes Landmesser, Alexandr Poprach, Hideki Takeshita, Giandomenico Roviello, Zin W. Myint, Lazar Popovic, Andrey Soares, Halima Abahssain, Patrizia Giannatempo, Javier Molina‐Cerrillo, Lorena Incorvaia, Samer Salah, Annalisa Zeppellini, Fernando Sabino Marques Monteiro, Camillo Porta, Shilpa Gupta, Matteo Santoni

Subjects: Get full text

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects by Yufei Wang, Guangliang Li, Hanying Wang, Quan Qi, Xian Wang, Haiqi Lu

Subjects: Get full text

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab by Benjamin Müller, Riccardo Curatolo, Hazem Juratli, Almir Husic, Josephine Nehring, Eliska Potlukova, Angela Kohler

Subjects: “…enfortumab vedotin…”
Get full text

Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy by Shota Kaburaki, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Kazuo Kasahara, Yasuhiro Terasaki, Masahiro Seike

Subjects: “…Enfortumab vedotin…”
Get full text

Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges by Fanhao Zeng, Qingjie Han, Tao Ding, Chao Tian, Maolin Jiang

Subjects: Get full text